



## The Immune System in Cancer

Guest Editor:

**Prof. Dr. Ayman J. Oweida**

Department of Nuclear Medicine  
and Radiobiology, Faculty of  
Medicine and Health Sciences,  
Université de Sherbrooke,  
Sherbrooke, QC J1H 5N4, Canada

Deadline for manuscript  
submissions:

**31 December 2024**

### Message from the Guest Editor

Dear Colleagues,

Our current knowledge of the tumor microenvironment (TME) is unprecedented and there's much to exploit for developing novel and effective therapies against cancer. In particular, immune cells represent a major component of many solid tumors and their activation can lead to effective anti-tumor immunity. The use of cancer vaccines has increased significantly in recent years. Many questions remain unanswered: how can they be effectively combined with other therapies? what are the best most effective means to deliver cancer vaccines? why do some patients respond while others have inherent resistance? how does acquired resistance develop and how to over come it? and what is the underlying biology behind the cross-talk between immune cells and the various components of the TME (tumor cells, endothelial cells, fibroblasts)? This special issue, titled "The Immune System in Cancer" will help bridge the existing knowledge gap and provide some answers to these questions. We welcome all types of submissions under this theme related to tumor immunology and the microenvironment.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

Vaccines Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)